, 2023, vol
Date ENHANCED EXTENDS PEPTIDE PLATFORM WITH TOPICAL GHK-CU, FORMULATED UNDER MEDICAL COMMISSION OVERSIGHT -- Prescription Topical Peptide Delivers a Consistent, Clinician-Prescribed Dose of GHK-Cu in Each Application -- -- Available Now on the Live Enhanced Platform -- New York April 28, 2026 Enhanced today announced an exciting new addition to its peptide catalog with the launch of a prescription-dosed topical GHK-Cu cream
For the expanded use of Leniolisib as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome
Treatment response depends on deficiency severity, route of administration, underlying cause, patient age, concurrent medical conditions, and medication interactions
Fibroblast growth factor-induced motor end plate regeneration in atrophic muscle
GHK-Cu is under research for its ability to stimulate fibroblast activity, enhance antioxidant defenses, and promote wound healing through modulation of gene expression related to tissue repair